Hormonal Therapy Story: How Laura-Lynn Renner Made an Informed Choice
By Kris Conner | August 7, 2024 How the Read More
Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris.
PUBLICATION: Transl Oncol. 2019 Sep 9;12(12):1557-1565. doi: 10.1016/j.tranon.2019.08.008. AUTHORS: Slembrouck Read More
MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology
PUBLICATION: Journal of Molecular Diagnostics September 2019 Volume 21, Issue Read More
Prospective Validation of a Genomic Assay in Breast Cancer: The 70-Gene MammaPrint Assay and the MINDACT Trial
PUBLICATION: Acta Medica Academica. Volume 48 (2) August 2019 AUTHOR: Read More
ASCO June 5 2019: Race and response to neoadjuvant chemotherapy
AUTHORS: Raquel Nunes, Femke de Snoo, Lisette Stork-Sloots, Tina Treece, Read More
2019 ASCO FLEX Poster
AUTHORS: Gordan Srkalovic, Adam Brufsky, Jennifer Crozier, Mehran Habibi, Pat Read More
Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study
PUBLICATION: Breast Cancer Res Treat. (2019) 175: 389. https://doi.org/10.1007/s10549-018-05075-x. AUTHORS: Read More
2018 SABCS FLEX Trials in Progress Poster
AUTHORS: Adam M. Brufsky, Jennifer A. Crozier, Ian Grady, Thomas Read More
Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay GalleryAssociation of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay
Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay
PUBLICATION: JAMA Oncol. 2018; 4(1):e173470. doi:10.1001/jamaoncol.2017.3470. AUTHORS: Michaela Tsai, MD; Read More
Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades
PUBLICATION: JAMA Oncol. 2017;3(11):1503-1510. doi:10.1001/jamaoncol.2017.1261. AUTHORS: Laura J. Esserman, MD, Read More
